A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

Inclusion Criteria:

Males and females 20 - 50 years of age, inclusive 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening

Or,

Individuals of child-bearing potential must have a negative screening urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

• Double-barrier method

• Intrauterine devices

• Non-heterosexual lifestyle and agrees to use contraception if planning on changingto heterosexual partner(s)

• Vasectomy of partner at least 6 months prior to screening

• Abstinence and agrees to use contraception if planning on becoming sexually activeduring the study 3. Subjects with elevated fasting glucose > 5.6 mmol/L (> 100mg/dL) and < 7.0 mmol/L (< 126 mg/dL) and/or elevated HbA1c (6.0-6.4%) and two ormore of the other following markers associated with metabolic syndrome at screening:

1. Abdominal obesity: waist circumference > 102 cm (40 inches) in men and > 88 cm (35 inches) in women

2. Hypertension: systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg

3. Elevated TG: > 150 mg/dL (1.7 mmol/L)

4. Low HDL-C: < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL (1.29 mmol/L) inwomen 4. Stable body weight defined as a <5% change in body weight in the threemonths prior to baseline, as assessed by the Qualified Investigator (QI) 5.Agrees to maintain current lifestyle habits (diet, physical activity,medications, supplements, and sleep) as much as possible throughout the study

5. Agrees to comply with dietary guidelines and study requirements prior toin-clinic visits (see Section 9.1) 7. Provided voluntary, written, informedconsent to participate in the study 8. Otherwise healthy as determined bymedical history and laboratory results as assessed by Qualified Investigator (QI)

Exclusion Criteria:

1. Individuals who are pregnant, breast feeding, or planning to become pregnant duringthe study

2. Allergy, sensitivity or intolerance, preventing consumption of investigationalproduct, placebo, or standardized meal

3. Poor venous access as assessed by the QI

4. Current use of prescribed and/or over-the-counter (OTC) medications, supplements,and/or consumption of food/drinks that may impact the glucose metabolism or efficacyof the investigational product (Sections 7.3.1 and 7.3.2)

5. Unstable metabolic disease or chronic diseases as assessed by the QI

6. Current or history of any significant diseases of the gastrointestinal tract asassessed by the QI

7. Unstable hypertension. Treatment on a stable dose of medication for at least 3months will be considered by the QI

8. Type I or Type II diabetes

9. Significant cardiovascular event in the past 6 months. Participants with nosignificant cardiovascular event on stable medication may be included afterassessment by the QI on a case-by-case basis

10. History of or current diagnosis with kidney and/or liver diseases as assessed by theQI on a case-by-case basis, with the exception of history of kidney stones inparticipants who are symptom free for 6 months

11. Self-reported confirmation of current or pre-existing thyroid condition. Treatmenton a stable dose of medication for at least 3 months will be considered by the QI

12. Major surgery in the past 3 months or individuals who have planned surgery duringthe course of the study. Participants with minor surgery will be considered on acase-by-case basis by the QI

13. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy orradiation with a follow up that is negative. Volunteers with cancer in fullremission for more than five years after diagnosis are acceptable

14. Individuals with an autoimmune disease or are immune compromised as assessed by theQI

15. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis asassessed by the QI

16. Self-reported confirmation of blood/bleeding disorders as assessed by the QI

17. Chronic inhalation or edible use of cannabinoid products (>1 time/month). Occasionalusers must agree to abstain from use while participating in the study

18. Regular use of tobacco or nicotine products in the past six months, as assessed bythe QI. Occasional users will be required to washout and abstain for the duration ofthe study period

19. Alcohol intake average of >2 standard drinks per day as assessed by the QI

20. Alcohol or drug abuse within the last 12 months

21. Clinically significant abnormal laboratory results at screening as assessed by theQI

22. Blood donation 30 days prior to baseline, during the study, or a planned donationwithin 30 days of the last study visit

23. Participation in other clinical research studies 30 days prior to baseline asassessed by the QI

24. Individuals who are unable to give informed consent

25. Any other condition or lifestyle factor, that, in the opinion of the QI, mayadversely affect the participant's ability to complete the study or its measures orpose significant risk to the participant